HAEMATOLOGICA:过氧化物酶体增殖物激活受体 α 在高脂血症下促进血小板高反应性和血栓形成中的关键作用

2021-10-09 MedSci原创 MedSci原创

血小板ppar α 会严重介导血小板活化,并有助于高脂血症下的血栓形成状态

      基于血小板过度活跃的动脉粥样硬化血栓性疾病是世界范围内死亡和发病率的主要原因。血小板高反应性和动脉粥样硬化血栓形成风险增加与血脂异常特别相关。过氧化物酶体增殖物激活受体 α (ppar α) 是脂质代谢的重要调节剂。尽管人们积极努力建立血脂异常中导致血小板过度活跃的通路,但其相关机制仍不清楚。识别血脂异常调节血小板活性的关键靶点对于预防和管理动脉粥样硬化血栓性疾病至关重要。

 

 

在这项研究中,研究了ppar α 在与血脂异常相关的血小板活化和血栓形成中的作用及其机制。使用缺失ppar α (ppar α -/-) 的小鼠,研究团队证明ppar α 是血小板活化和血栓形成所必需的。Ppar α 的作用主要取决于血小板致密颗粒的分泌,并由p38MAPK/Akt,脂肪酸 β-氧化和NAD(P)H氧化酶 (NOX) 途径引起。重要的是,ppar α 和相关途径介导了高脂饮食 (HFD) 诱导的血栓前状态和氧化的低密度脂蛋白 (oxLDL) 引起的血小板过度活跃。野生型 (WT),嵌合 (ppar α/-) 和ppar α -/-小鼠的数据显示,血小板反应性与ppar α 的表达水平呈正相关。这种正相关关系在高脂血症患者的血小板中得到概括。在脂质处理的巨核细胞系中,脂质诱导的活性氧 (ROS)-NF-κ b途径被发现在高脂血症中上调血小板ppar α。这些数据表明,血小板ppar α 会严重介导血小板活化,并有助于高脂血症下的血栓形成状态。

综上所述,他们发现血小板PPARα通过促进颗粒密集分泌,正向介导血小板活化。高脂血症可能通过上调巨核细胞/血小板中PPARα的表达和PPARα在血小板中介导的激活信号的增强来促进血栓前状态。这项工作表明,针对PPARα的基因组和非基因组联合干预可能对预防高脂血症下的血栓形成是必要的。

原始出处:

Li L, Zhou J, Wang S, Jiang L, Chen X, Zhou Y, Li J, Shi J, Liu P, Shu Z, Gonzalez FJ, Liu A, Hu H. Critical role of peroxisome proliferator-activated receptor α in promoting platelet hyperreactivity and thrombosis under hyperlipidemia. Haematologica; https://doi.org/10.3324/haematol.2021.279770 [Early view].

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2022868, encodeId=3aaa202286877, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Nov 14 22:18:47 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080002, encodeId=bebf208000243, content=<a href='/topic/show?id=63a589062d8' target=_blank style='color:#2F92EE;'>#血小板高反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89062, encryptionId=63a589062d8, topicName=血小板高反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Fri Feb 25 12:18:47 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008533, encodeId=c5dc200853304, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Apr 28 22:18:47 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797071, encodeId=afea1e970714e, content=<a href='/topic/show?id=045222331db' target=_blank style='color:#2F92EE;'>#中的关键作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22331, encryptionId=045222331db, topicName=中的关键作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Jan 14 17:18:47 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317660, encodeId=f50b131e66009, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574678, encodeId=4fff15e4678d2, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2022868, encodeId=3aaa202286877, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Nov 14 22:18:47 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080002, encodeId=bebf208000243, content=<a href='/topic/show?id=63a589062d8' target=_blank style='color:#2F92EE;'>#血小板高反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89062, encryptionId=63a589062d8, topicName=血小板高反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Fri Feb 25 12:18:47 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008533, encodeId=c5dc200853304, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Apr 28 22:18:47 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797071, encodeId=afea1e970714e, content=<a href='/topic/show?id=045222331db' target=_blank style='color:#2F92EE;'>#中的关键作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22331, encryptionId=045222331db, topicName=中的关键作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Jan 14 17:18:47 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317660, encodeId=f50b131e66009, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574678, encodeId=4fff15e4678d2, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2022868, encodeId=3aaa202286877, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Nov 14 22:18:47 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080002, encodeId=bebf208000243, content=<a href='/topic/show?id=63a589062d8' target=_blank style='color:#2F92EE;'>#血小板高反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89062, encryptionId=63a589062d8, topicName=血小板高反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Fri Feb 25 12:18:47 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008533, encodeId=c5dc200853304, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Apr 28 22:18:47 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797071, encodeId=afea1e970714e, content=<a href='/topic/show?id=045222331db' target=_blank style='color:#2F92EE;'>#中的关键作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22331, encryptionId=045222331db, topicName=中的关键作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Jan 14 17:18:47 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317660, encodeId=f50b131e66009, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574678, encodeId=4fff15e4678d2, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
    2022-04-28 changfy
  4. [GetPortalCommentsPageByObjectIdResponse(id=2022868, encodeId=3aaa202286877, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Nov 14 22:18:47 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080002, encodeId=bebf208000243, content=<a href='/topic/show?id=63a589062d8' target=_blank style='color:#2F92EE;'>#血小板高反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89062, encryptionId=63a589062d8, topicName=血小板高反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Fri Feb 25 12:18:47 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008533, encodeId=c5dc200853304, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Apr 28 22:18:47 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797071, encodeId=afea1e970714e, content=<a href='/topic/show?id=045222331db' target=_blank style='color:#2F92EE;'>#中的关键作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22331, encryptionId=045222331db, topicName=中的关键作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Jan 14 17:18:47 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317660, encodeId=f50b131e66009, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574678, encodeId=4fff15e4678d2, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2022868, encodeId=3aaa202286877, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Nov 14 22:18:47 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080002, encodeId=bebf208000243, content=<a href='/topic/show?id=63a589062d8' target=_blank style='color:#2F92EE;'>#血小板高反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89062, encryptionId=63a589062d8, topicName=血小板高反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Fri Feb 25 12:18:47 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008533, encodeId=c5dc200853304, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Apr 28 22:18:47 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797071, encodeId=afea1e970714e, content=<a href='/topic/show?id=045222331db' target=_blank style='color:#2F92EE;'>#中的关键作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22331, encryptionId=045222331db, topicName=中的关键作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Jan 14 17:18:47 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317660, encodeId=f50b131e66009, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574678, encodeId=4fff15e4678d2, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
    2021-10-11 fengyi812
  6. [GetPortalCommentsPageByObjectIdResponse(id=2022868, encodeId=3aaa202286877, content=<a href='/topic/show?id=188b3e7309c' target=_blank style='color:#2F92EE;'>#反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37730, encryptionId=188b3e7309c, topicName=反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7532500500, createdName=12499e01m47暂无昵称, createdTime=Sun Nov 14 22:18:47 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2080002, encodeId=bebf208000243, content=<a href='/topic/show?id=63a589062d8' target=_blank style='color:#2F92EE;'>#血小板高反应性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89062, encryptionId=63a589062d8, topicName=血小板高反应性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c64275, createdName=piaojinhua, createdTime=Fri Feb 25 12:18:47 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2008533, encodeId=c5dc200853304, content=<a href='/topic/show?id=1066844469' target=_blank style='color:#2F92EE;'>#HAE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8444, encryptionId=1066844469, topicName=HAE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32d177, createdName=changfy, createdTime=Thu Apr 28 22:18:47 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797071, encodeId=afea1e970714e, content=<a href='/topic/show?id=045222331db' target=_blank style='color:#2F92EE;'>#中的关键作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22331, encryptionId=045222331db, topicName=中的关键作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Fri Jan 14 17:18:47 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317660, encodeId=f50b131e66009, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574678, encodeId=4fff15e4678d2, content=<a href='/topic/show?id=9b56102616bb' target=_blank style='color:#2F92EE;'>#高脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102616, encryptionId=9b56102616bb, topicName=高脂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3b716021149, createdName=pcw111, createdTime=Mon Oct 11 08:18:47 CST 2021, time=2021-10-11, status=1, ipAttribution=)]
    2021-10-11 pcw111

相关资讯

防控有道,风险管理丨杨斌:多支病变“脂低有生”

青岛大学附属医院心内科杨斌医师分享了2例ASCVD多支病变超高危患者,并伴有高脂血症。该患者联合使用PCSK9抑制剂后,低密度脂蛋白胆固醇迅速达标,LDL-C水平应降至<1.4 mmol/L。

BMJ Open:一项横断面研究:中国非吸烟女性儿童时期二手烟暴露与患高脂血症和冠心病的联系

二手烟(SHS)指的是从燃烧的烟头和活跃烟民呼出烟雾中气体和粒子的混合物。目前的研究结果表明,暴露于SHS与各种健康问题有关,如2型糖尿病、高血压、非酒精性脂肪肝、卒中、心血管疾病、肺癌以及较于不吸烟

中国自主研发抗高脂血症化学1类新药DC371739进入临床试验

由中国科学院上海药物研究所柳红、王逸平和蒋华良课题组联合研发的抗高血脂症化学1类新药DC371739,于2020年7月24日获得国家药品监督管理局颁发的临床试验通知书,同意开展临床试验。

惋惜!31岁安徽小伙一觉醒来偏瘫了!原来竟和他这个十多年的习惯有关……

家住杭州的小李今年31岁,从老家安徽来杭奋斗的他是杭州市区一家餐饮店的合伙人,平时店里生意很红火,生活忙碌的他平时也不忘健身锻炼,身体一直很健康。然而平静的生活却在上个月的一个早晨被打破了。

高脂血症的常用药物,一网打尽!

血脂和脂蛋白代谢乱与动脉粥样硬化密切相关,血脂异常的治疗目的在于降低缺血性心血管疾病(冠心病和缺血性脑卒中)的患病率和死亡率。

ATVB:我国学者:高血脂不仅引起心脑血管病,还会增COVID-19风险!

较高的总胆固醇和载脂蛋白水平可能会增加COVID-19的感染风险。

拓展阅读

银蓝调脂胶囊:破解小鼠高脂血症的代谢密码!

该研究探讨了高脂血症小鼠YL降脂的机制和途径。

Cardiovasc Diabetol:高脂血症和体脂分布对肥胖患者亚临床左心室功能的影响

高脂血症与肥胖患者亚临床左室舒张功能障碍独立相关。中心脂肪分布与亚临床左室功能呈负相关,外周脂肪分布与亚临床左室功能呈正相关。

痴呆风险升高51%!北大&协和医学院团队研究:高血脂的人要注意

近日,Journal of the American Medical Directors Association发表一项纵向队列研究,表明确诊高脂血症的年龄越小,后续发生痴呆的风险就越高。

J Ethnopharmacol:绞股蓝苷元对高脂肪饮食大鼠的降血脂作用和肠道菌群调节

探讨绞股蓝苷元(Agl)对高脂饮食(HFD)诱导的高脂血症大鼠模型的潜在治疗作用。

检验人:遇到脂血、乳糜血该怎么办?

本文就高脂血症中乳糜血样本和脂血样本进行区分介绍并提供简易处理方法。

BMC MED:评估中国青少年服用调脂药物的安全性——药物靶点孟德尔随机研究

他汀类药物和 PCSK9 抑制剂在东亚青少年中似乎是安全的,但未来需要进行更大规模的研究来验证这些发现。

《成人高脂血症食养指南(2023年版)》解读

首都医科大学附属北京中医医院心内科 · 2023-08-01

《成人高脂血症食养指南(2023年版)》问答

中华人民共和国国家卫生健康委员会 · 2023-01-18

成人高脂血症食养指南(2023年版)

中华人民共和国国家卫生健康委员会 · 2023-01-12

成人高脂血症食养指南(征求意见稿)

国民营养健康指导委员会办公室 · 2022-11-29